132 related articles for article (PubMed ID: 38341178)
1. Nano-chemical priming strategy to enhance TGF-β resistance and anti-tumor activity of natural killer cells.
Choi SH; Cho HB; Choi JH; Kim HJ; Jang HJ; Cho S; Maeng E; Park H; Ryu KS; Park KH; Park KS
J Control Release; 2024 Mar; 367():768-778. PubMed ID: 38341178
[TBL] [Abstract][Full Text] [Related]
2. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway.
Zhao Y; Hu J; Li R; Song J; Kang Y; Liu S; Zhang D
Onco Targets Ther; 2015; 8():1553-9. PubMed ID: 26124672
[TBL] [Abstract][Full Text] [Related]
3. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
4. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
[TBL] [Abstract][Full Text] [Related]
5. Chemical priming of natural killer cells with branched polyethylenimine for cancer immunotherapy.
Choi SH; Kim HJ; Park JD; Ko ES; Lee M; Lee DK; Choi JH; Jang HJ; Kim I; Jung HY; Park KH; Park KS
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36028281
[TBL] [Abstract][Full Text] [Related]
6. Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.
Chaudhry K; Dowlati E; Long MD; Geiger A; Lang H; Gomez EC; Muniraj N; Sanchez CE; Singh PK; Liu S; Bollard CM; Cruz CRY
Cytotherapy; 2022 Aug; 24(8):802-817. PubMed ID: 35589475
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Otegbeye F; Ojo E; Moreton S; Mackowski N; Lee DA; de Lima M; Wald DN
PLoS One; 2018; 13(1):e0191358. PubMed ID: 29342200
[TBL] [Abstract][Full Text] [Related]
8. Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β.
Brownlie D; Doughty-Shenton D; Yh Soong D; Nixon C; O Carragher N; M Carlin L; Kitamura T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472858
[TBL] [Abstract][Full Text] [Related]
9. Boosting Natural Killer Cell-Based Cancer Immunotherapy with Selenocystine/Transforming Growth Factor-Beta Inhibitor-Encapsulated Nanoemulsion.
Liu C; Lai H; Chen T
ACS Nano; 2020 Sep; 14(9):11067-11082. PubMed ID: 32806028
[TBL] [Abstract][Full Text] [Related]
10. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
11. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
12. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.
Yvon ES; Burga R; Powell A; Cruz CR; Fernandes R; Barese C; Nguyen T; Abdel-Baki MS; Bollard CM
Cytotherapy; 2017 Mar; 19(3):408-418. PubMed ID: 28109751
[TBL] [Abstract][Full Text] [Related]
13. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Kopp HG; Placke T; Salih HR
Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
[TBL] [Abstract][Full Text] [Related]
14. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M; Arlen PM; Tsang KY
Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
[TBL] [Abstract][Full Text] [Related]
16. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.
Wilson EB; El-Jawhari JJ; Neilson AL; Hall GD; Melcher AA; Meade JL; Cook GP
PLoS One; 2011; 6(9):e22842. PubMed ID: 21909397
[TBL] [Abstract][Full Text] [Related]
17. Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors.
Pierson BA; Gupta K; Hu WS; Miller JS
Blood; 1996 Jan; 87(1):180-9. PubMed ID: 8547640
[TBL] [Abstract][Full Text] [Related]
18. Selenadiazole derivative-loaded metal azolate frameworks facilitate NK cell immunotherapy by sensitizing tumor cells and shaping immuno-suppressive microenvironments.
Yang Y; Jiang Y; Xie B; Shi S; Pi F; Chen M; Sang C; Xu L; Chen T
Biomater Sci; 2023 Feb; 11(4):1517-1529. PubMed ID: 36606484
[TBL] [Abstract][Full Text] [Related]
19. An IL-15 superagonist/IL-15Rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression.
Fujii R; Jochems C; Tritsch SR; Wong HC; Schlom J; Hodge JW
Cancer Immunol Immunother; 2018 Apr; 67(4):675-689. PubMed ID: 29392336
[TBL] [Abstract][Full Text] [Related]
20. TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer.
Wong JKM; McCulloch TR; Alim L; Omer N; Mehdi AM; Tuong ZK; Bonfim-Melo A; Chung E; Nicol A; Simpson F; Rhee H; Rossi GR; Souza-Fonseca-Guimaraes F
EBioMedicine; 2024 May; 104():105176. PubMed ID: 38810560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
